Related Experiment Videos

[Precautions for use and contraindications of thiazolidinediones. A cardiologist opinion]

A Cohen-Solal1

  • 1Service de Cardiologie, Hôpital Beaujon, F - 92110 Clichy, France.

Annales D'Endocrinologie
|May 31, 2002
PubMed

Insights

Thiazolidinediones are contraindicated in type 2 diabetes patients with heart failure. Physicians should carefully manage patients at risk, consulting cardiologists when necessary for safe thiazolidinedione use.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • European marketing authorization for thiazolidinediones (rosiglitazone, pioglitazone) contraindicates use in patients with cardiac failure.
  • Fluid retention and cardiac failure are significant concerns associated with thiazolidinedione use.

Purpose of the Study:

  • To review current experimental and clinical data on thiazolidinediones and cardiac failure.
  • To provide guidance for physicians on initiating and managing thiazolidinediones in type 2 diabetic patients, especially those at risk for cardiac issues.

Main Methods:

  • Review of available experimental and clinical data.
  • Analysis of European marketing authorization contraindications and warnings.
  • Development of prescribing and management guidelines.

Main Results:

  • Thiazolidinediones carry risks of fluid retention and cardiac failure.
  • Contraindications exist for patients with existing or historical cardiac failure.
  • Cardiologist consultation and echocardiography are recommended for uncertain cases.

Conclusions:

  • Physicians must exercise caution when prescribing thiazolidinediones to type 2 diabetic patients.
  • Risk assessment for cardiac failure is crucial before and during treatment.
  • Specialized cardiac evaluation is advised for high-risk individuals or when clinical doubt arises.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...